Ishara Investments LP — 13F Holdings & Portfolio
CIK 2111609 · latest 13F-HR filed 2026-08-14
Ishara Investments LP manages $136.1M in 13F-reported U.S. long-equity assets across 41 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ACAD (7.62%), XERS (7.16%), BMRN (6.03%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 16 new positions and exited 11; 15 existing positions rose in reported value and 7 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
3 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 51%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 19, 2026.
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| BERMAN, SETH, IRA Control | CHIEF COMPLIANCE OFFICER/CHIEF FINANCIAL OFFICER since Apr 2024 | Less than 5% | Individual |
| ISHARA INVESTMENTS GP LLC Control | GENERAL PARTNER since Aug 2023 | Less than 5% | Domestic Entity |
| MEHRA, SHAUN, RAVI Control | FOUNDER, LIMITED PARTNER since Aug 2023 | 75% or more | Individual |
| MEHRA, SHAUN, RAVI Control Indirect owner via ISHARA INVESTMENTS GP LLC | MEMBER since Aug 2023 | 75% or more | Individual |
Ownership & leadership changes · 1 filing with changes since Nov 15, 2024
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedISHARA PARTNERS GP LLC · GENERAL PARTNER · Less than 5% · control person · listed since Aug 2023
- No longer listedMEHRA, SHAUN, RAVI · MEMBER · 75% or more · indirect via ISHARA PARTNERS GP LLC · control person · listed since Aug 2023
- AddedISHARA INVESTMENTS GP LLC · GENERAL PARTNER · Less than 5% · control person
- AddedMEHRA, SHAUN, RAVI · MEMBER · 75% or more · indirect via ISHARA INVESTMENTS GP LLC · control person
- ListedBERMAN, SETH, IRA · CHIEF COMPLIANCE OFFICER/CHIEF FINANCIAL OFFICER · Less than 5% · control person
- ListedISHARA PARTNERS GP LLC · GENERAL PARTNER · Less than 5% · control person
- ListedMEHRA, SHAUN, RAVI · FOUNDER, LIMITED PARTNER · 75% or more · control person
- ListedMEHRA, SHAUN, RAVI · MEMBER · 75% or more · indirect via ISHARA PARTNERS GP LLC · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- ACADIA PHARMACEUTICALS INC$7.6M +278.9%
- XERIS BIOPHARMA HOLDINGS INC$3.8M +63.9%
- ANNEXON INC$3.7M +385.0%
- BIOMARIN PHARMACEUTICAL INC$3.6M +77.3%
- ULTRAGENYX PHARMACEUTICAL IN$3.2M +87.5%
Top Trims
- AXSOME THERAPEUTICS INC.-$2.9M -42.1%
- VERA THERAPEUTICS INC-$2.9M -86.7%
- IMMATICS N.V-$1.2M -79.4%
- SCHOLAR ROCK HLDG CORP-$1.1M -40.1%
- SIONNA THERAPEUTICS INC-$621.9K -31.5%
New Positions
- AGIOS PHARMACEUTICALS INC$6.1M
- INSMED INC$5.5M
- CRINETICS PHARMACEUTICALS IN$5.4M
- TONIX PHARMACEUTICALS HLDG C$4.3M
- BRIDGEBIO PHARMA INC$4.3M
Exited Positions
- KALVISTA PHARMACEUTICALS INC$5.6M
- AMICUS THERAPEUTIC$5.3M
- VERASTEM INC$4.3M
- ARROWHEAD PHARMACEUTICALS IN$3.5M
- MOONLAKE IMMUNOTHERAPEUTICS$3.2M
Ishara Investments LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ACADIA PHARMACEUTICALS INC | ACAD | 004225108 | $10.4M | 7.62% | 410,000 | SH |
| 2 | XERIS BIOPHARMA HOLDINGS INC | XERS | 98422E103 | $9.7M | 7.16% | 1,230,000 | SH |
| 3 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $8.2M | 6.03% | 143,500 | SH |
| 4 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $7.5M | 5.55% | 22,550 | SH |
| 5 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 90400D108 | $6.8M | 5.03% | 205,000 | SH |
| 6 | AGIOS PHARMACEUTICALS INC | AGIO | 00847X104 | $6.1M | 4.47% | 164,000 | SH |
| 7 | INSMED INC | INSM | 457669307 | $5.5M | 4.01% | 51,250 | SH |
| 8 | CRINETICS PHARMACEUTICALS IN | CRNX | 22663K107 | $5.4M | 3.95% | 143,500 | SH |
| 9 | ZENTALIS PHARMACEUTICALS INC | ZNTL | 98943L107 | $5.0M | 3.65% | 1,025,000 | SH |
| 10 | VAXCYTE INC | PCVX | 92243G108 | $4.8M | 3.50% | 82,000 | SH |
| 11 | ANNEXON INC | ANNX | 03589W102 | $4.7M | 3.44% | 820,000 | SH |
| 12 | TRAVERE THERAPEUTICS INC | TVTX | 89422G107 | $4.7M | 3.42% | 82,000 | SH |
| 13 | TONIX PHARMACEUTICALS HLDG C | TNXP | 890260839 | $4.3M | 3.17% | 338,250 | SH |
| 14 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $4.3M | 3.14% | 57,400 | SH |
| 15 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $4.0M | 2.95% | 16,400 | SH |
| 16 | CONTINEUM THERAPEUTICS INC | CTNM | 21217B100 | $3.4M | 2.47% | 205,000 | SH |
| 17 | LEXICON PHARMACEUTICALS INC | LXRX | 528872302 | $3.1M | 2.24% | 1,271,000 | SH |
| 18 | KURA ONCOLOGY INC | KURA | 50127T109 | $3.0M | 2.23% | 276,750 | SH |
| 19 | DBV TECHNOLOGIES S A | DBVT | 23306J309 | $3.0M | 2.22% | 184,500 | SH |
| 20 | GENMAB A/S | GMAB | 372303206 | $2.8M | 2.07% | 102,500 | SH |
| 21 | CYTOKINETICS INC | CYTK | 23282W605 | $2.8M | 2.05% | 32,800 | SH |
| 22 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $2.8M | 2.03% | 102,500 | SH |
| 23 | SILENCE THERAPEUTICS PLC | SLN | 82686Q101 | $2.4M | 1.79% | 55,350 | SH |
| 24 | NUVATION BIO INC | NUVB | 67080N101 | $2.1M | 1.54% | 369,000 | SH |
| 25 | WAVE LIFE SCIENCES LTD | WVE | Y95308105 | $1.9M | 1.40% | 328,000 | SH |
| 26 | NEKTAR THERAPEUTICS | NKTR | 640268306 | $1.9M | 1.37% | 26,650 | SH |
| 27 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $1.7M | 1.24% | 30,750 | SH |
| 28 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $1.7M | 1.22% | 32,800 | SH |
| 29 | ALNYLAM PHARMACEUTICALS INC | ALNY | 02043Q107 | $1.5M | 1.13% | 5,125 | SH |
| 30 | BEAM THERAPEUTICS INC | BEAM | 07373V105 | $1.4M | 1.03% | 41,000 | SH |
| 31 | SIONNA THERAPEUTICS INC | SION | 829401108 | $1.4M | 0.99% | 123,000 | SH |
| 32 | ORIC PHARMACEUTICALS INC | ORIC | 68622P109 | $1.3M | 0.98% | 123,000 | SH |
| 33 | NEWAMSTERDAM PHARMA COMPANY | NAMS | N62509109 | $1.3M | 0.92% | 36,900 | SH |
| 34 | VERTEX PHARMACEUTICALS INC | VRTX | 92532F100 | $1.2M | 0.90% | 2,460 | SH |
| 35 | ARS PHARMACEUTICALS INC | SPRY | 82835W108 | $1.1M | 0.84% | 143,490 | SH |
| 36 | MONOPAR THERAPEUTICS INC | MNPR | 61023L207 | $1.1M | 0.84% | 12,300 | SH |
| 37 | ERASCA INC | ERAS | 29479A108 | $751.1K | 0.55% | 41,000 | SH |
| 38 | VERA THERAPEUTICS INC | VERA | 92337R101 | $439.8K | 0.32% | 10,250 | SH |
| 39 | IMMATICS N.V | IMTX | N44445109 | $311.5K | 0.23% | 30,750 | SH |
| 40 | MEREO BIOPHARMA GROUP PLC | MREO | 589492107 | $244.2K | 0.18% | 768,750 | SH |
| 41 | GOSSAMER BIO INC | GOSS | 38341P102 | $135.0K | 0.10% | 820,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $136.1M | 41 | 0002111609-26-000004 |
| 2026-03-31 | 2026-05-15 | $105.6M | 37 | 0002111609-26-000002 |
| 2025-12-31 | 2026-02-17 | $87.5M | 38 | 0002111609-26-000001 |
LOS ANGELES, CA 90034